ATKINS M SHAN sold $3K of CGC

ATKINS M SHAN sold 3,197 shares of Canopy Growth Corp (CGC) at $0.92 on 2026-06-26.

Original reporting
SEC EDGAR · ATKINS M SHAN
Published Jun 29, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
high confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value) and post-transaction holdings; it does not include any operational or financial update for CGC.

02

Market read

Traders may briefly reassess CGC sentiment due to insider selling, but the disclosed transaction is small and lacks a new fundamental catalyst.

03

What to watch

Director sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, the signal-to-noise is low.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-29 after-hours; reflects sale executed 2026-06-26.

Background

The article is an SEC Form 4 insider transaction disclosure for Canopy Growth Corp (CGC).

Company-level read

Ticker impact

$CGCNeutralHigh confidence
Context

Form 4 shows Canopy Growth director ATKINS M SHAN sold 3,197 shares on 2026-06-26 at $0.9237 for ~$2,953.

Expected impact

Low likelihood of a sustained price move from this single small insider sale; any impact would be sentiment-only and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with small dollar value and no stated new company-specific catalyst (no guidance, deal, or regulatory action).

Market effects

Minimal—this is company-specific insider dealing with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan, some traders may interpret it as a mild negative signal, even if the dollar amount is small.

Key entities

  • Canopy Growth Corp

    Subject of the Form 4 insider transaction; director sold 3,197 shares at $0.9237 on 2026-06-26.

  • ATKINS M SHAN

    Director who executed the reported sale; holdings after transaction: 146,517 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.